SEATTLE — June 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. If you are covering news at the annual meeting of the American Society of Clinical Oncology (June 4-8), check out our ASCO page highlighting Fred Hutch presentations and feel free to reach out to our media team for help sourcing experts: media@fredhutch.
Fred Hutchinson Cancer Research Center has announced 12 recipients of the 2021 Dr. Eddie Méndez award, honoring a physician-scientist and cherished colleague at Fred Hutch. The recipients are postdoctoral researchers from across the U.S. with research expertise in cancer, infectious disease and basic sciences.
SEATTLE — May 4, 2021 — Below are summaries of recent Fred Hutch research findings and other news.If you are covering news at the upcoming American Society of Gene & Cell Therapy, American Society of Clinical Oncology, or other conferences, feel free to reach out to our media team for help sourcing experts: media@fredhutch.
SEATTLE — April 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. April is National Minority Health Month, with a focus on the disproportionate impacts of COVID-19 on communities of color. See more details below on related Fred Hutch programming.Save the date for our monthly public science event, “Science Says” on Tuesday, April 27.
SEATTLE — March 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.March is Women’s History month. We’d like to honor Dottie Thomas, known as the “mother of bone marrow transplantation.” She spent years working as a research partner alongside her husband, Nobel Prize-winning Dr.
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
SEATTLE —Feb. 4, 2021 —Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.We are looking forward to the Transplantation & Cellular Therapy Meetings, to be held online Feb. 8-12. Read highlights of Fred Hutch research to be presented, including on COVID-19 and cancer and new insights on treating graft-vs.
SEATTLE —Jan. 6, 2020 —Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.Scientists predict progress against COVID-19, cancer in 2021 Just as the COVID-19 pandemic dominated our lives in 2020, it was a huge focus for many researchers at Fred Hutch.
SEATTLE – Dec. 2, 2020 – Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.If you’re following the American Society of Hematology’s annual meeting (virtual, Dec. 5-8), see our media tip sheet highlighting Fred Hutch presentations and activities, including those by current ASH president Dr.
SEATTLE — Nov. 18, 2020 — Fred Hutchinson Cancer Research Center’s latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 – 8.Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr.
After more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer Research Center have moved into their new labs at the newly renovated Lake Union Steam Plant.
SEATTLE — Oct. 5, 2020 — Fred Hutchinson Cancer Research Center announced the opening of the COVID-19 Clinical Research Center, or CCRC. Funded by philanthropic donations and public/private partnerships, the CCRC is one of the first stand-alone facilities in the nation designed to test novel interventions to treat and prevent COVID-19.
SEATTLE – Oct. 1, 2020 – Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.And if you’re looking for sources for October’s Breast Cancer Awareness Month, please see our breast cancer page for a list of projects, experts and the latest breast cancer news.
A new study published in the journal Critical Care Explorations shows for the first time that part of the stress response in people and animals involves increasing the levels of a naturally circulating element in blood. The discovery demonstrates a biological mechanism that rapidly responds to severe physiologic stress and potentially serves to protect us from further damage due to life-threatening conditions.
Fred Hutchinson Cancer Research Center and its clinical-care partner, Seattle Cancer Care Alliance, announced today the organizations are receiving a $500,000 grant from Bank of America for COVID-19 relief.
Fred Hutchinson Cancer Research Center is launching a new COVID-19 research project called CovidWatch. This volunteer longitudinal study, aims to answer some of the most important questions about COVID-19
Scientists at Fred Hutchinson Cancer Research Center identified a tiny protein in scorpion venom that rapidly accumulates in joint cartilage. Then they linked these mini-proteins with steroids to reverse inflammation in rats with arthritis. The researchers found that the drugs concentrated in the joints, potentially avoiding the body-wide toxicities and infection risks caused by nontargeted steroid treatment.
Fred Hutchinson Cancer Research Center will host a press breakfast Feb. 14 at the annual meeting of the American Association for the Advancement of Science, to be held Feb. 13-16 in Seattle.
Fred Hutchinson Cancer Research Center announced today that Dr. Thomas J. Lynch Jr. will become the center’s new president and director. Lynch, a well-known cancer leader with expertise in solid tumor research, precision medicine and immuno-oncology, will join Fred Hutch Feb. 1.
Within weeks, CAR T cells targeting ovarian cancer cleared tumors in 70% of treated mice, shows study in Nature Biomedical Engineering. (Note: Images available for media use).
A team at Fred Hutchinson Cancer Research Center has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients.
A new multicenter analysis led by researchers at the Fred Hutchinson Cancer Research Center, the Icahn School of Medicine at Mount Sinai and other institutions found the inclusion of diverse, multiethnic populations in large-scale genomic studies is critical for reducing health disparities and accurately representing genetics-related disease risks in all populations. The results appear in the June 19 issue of the journal Nature.
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®.
Fred Hutchinson Cancer Research Center’s latest findings in immunotherapy, prevention of cancer-linked viruses, health care disparities and more will be showcased at the annual meeting of the American Society of Clinical Oncology. The conference, “Caring for Every Patient, Learning from Every Patient,” will be held May 31-June 4 in Chicago. See highlights below.
Scientists at Fred Hutchinson Cancer Research Center took a step toward making gene therapy more practical by simplifying the way gene-editing instructions are delivered to cells. Using a gold nanoparticle instead of an inactivated virus, they safely delivered gene-editing tools in lab models of HIV and inherited blood disorders, as reported May 27 in Nature Materials.
Right fielder honored for overcoming personal tragedy, demonstrating a commitment to scientific research and exemplifying the spirit of Fred Hutchinson
Fred Hutchinson Cancer Research Center’s latest findings in immunotherapies, nanoparticles to deliver gene therapy, the genetic underpinnings of cancer, insights on health disparities and more will be showcased at the annual meeting of the American Association for Cancer Research. The conference, “Integrative Cancer Science — Global Impact — Individualized Patient Care,” will be held March 29–April 3 in Atlanta.